<DOC>
	<DOCNO>NCT01167192</DOCNO>
	<brief_summary>The purpose study determine whether platinum-based chemotherapy ( either cisplatin carboplatin ) , give radiation therapy prior surgery , effective improve response treatment triple negative breast cancer patient . This treatment study type breast cancer respond well commonly use treatment tamoxifen herceptin .</brief_summary>
	<brief_title>Neoadjuvant Platinum-based Chemoradiation Therapy Locally Advanced Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patient must &gt; = 18 year age Patient must female Patient must primary invasive ductal breast adenocarcinoma either : 1. newly diagnose , without previous systemic treatment OR 2. fail respond &lt; = 4 cycle neoadjuvant anthracycline base therapy assess clinical exam image study ( mammogram , ultrasound breast MRI ) . Patient 's tumor must classify clinically stage T2 , T3 , T4 N ( NX , N0 , N1 , N2 , N3 ) prior neoadjuvant treatment . Patient must ECOG Performance Status &lt; = 1 . Patient must adequate organ function define : 1 . Renal Function : 1 . CrCl ≥ 60 ml/min patient receive cisplatin 2 . CrCl ≥ 30 ml/min patient receive carboplatin . 2 . Liver Function : 1 . ALT , AST , ALK Phos &lt; = 1.5 x upper limit institutional normal . 2 . Bilirubin &lt; = 1.5 x upper limit institutional normal . 3 . Normal leave ventricular function ( LVEF &gt; 50 % ) MUGA ECHO . 4 . Hematologic : 1 . Absolute Neutrophil Count &gt; = 1500/mcl 2 . Platelets &gt; = 100,000/mcl 3 . Hemoglobin &gt; = 8.0 g/dl Patient must able willing sign inform consent document . Patient must evidence distant metastasis present CT , bone scan , PETCT . If bone scan CT scan demonstrate indeterminate lesion , nature lesion clarify additional testing PET MRI discretion treat physician . Patients receive neoadjuvant anthracycline base therapy must undergo restaging exclude distant metastasis prior enrollment . Patient must prior malignancy exception curatively treat basal squamous carcinoma skin history previous malignancy , treat least great 5 year disease free survival . Patient 's tumor must express follow biomarkers must Allred score &lt; 4 : estrogen receptor , progesterone receptor , Her2/neu amplify . Women child bear potential may currently pregnant breastfeed time registration must agree use adequate contraception . Patient must &gt; = grade 2 peripheral neuropathy . Patient must know hear impairment ( hearing loss severe tinnitus ) . Hearing test perform discretion treat physician . Patient must previously treat cisplatin carboplatin condition .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>